You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Automated Monitoring of Chemotactic Cell Movement
SBC: APPLIED BIOPHYSICS, INC. Topic: N/ADESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
Combined Gene Therapy/Tissue Engineered Cartilage Repair
SBC: TISSUEGENESIS, INC. Topic: N/ADESCRIPTION (Verbatim from Applicant): The objective of this Phase I protocol is to develop a novel approach for the repair of articular cartilage using gene enhanced tissue engineering (GETE). Successful clinical repair of articular cartilage continues to be elusive. The current study seeks to repair articular cartilage defects using constructs containing cultured perio ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
COMPUTERIZED STEREOCAMPIMETER TO MEASURE CENTRAL SCOTOMA
SBC: OPTICOLOGY, INC. Topic: N/AThe proposed research intends to design and build an instrument of accurately measure centrally located pathological areas of non-vision, or central scotomas, within the 30 to 60 degrees field of vision. The new device is intended to serve as a supplement to commercially available automatic perimeters, which are known to be inaccurate when retinal defects are confined to the central field of visi ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
POC 2-D Diffusion Assay for self-monitoring of BNP
SBC: SENTILUS Topic: NHLBIDESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Science Take-Out Kits for Environmental Health Education
SBC: Science Take-Out, LLC Topic: NIEHSDESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New generation of catheters for treatment of atrial fibrillation
SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Atrial fibrillation remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality. Cryotherapy and radiofrequency catheter ablations for the purpose of eliminating atrial fibrillation have become a mainstream treatment option. They produce lesions that block the spread of elect ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel therapeutic approach for Acute Lung Injury/ARDS
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NHLBIDESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer
SBC: CUREFAKTOR PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIADESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health